The Celigo Image Cytometer has been previously used for a wide range of immuno-oncology and immunotherapy studies, demonstrating the great utility of this instrument to assess the activity of cytotoxic immune cells against malignant cells of interest.
For the development of new drugs and the advancement of new cell therapies, pharmaceutical companies have recurred to cytotoxicity assays as a quick way to assess the viability of cell lines in response to an external stimulus.
The ongoing pursuit of novel anti-cancer therapeutics must consider the potential for off-target effects on the immune system.
Syngeneic tumor models and human immune cell-engrafted mice are two of the popular preclinical tools in immuno-oncology studies.
Nexcelom Bioscience, a leading provider of cell counting and characterization products for the life science industry, announced the launch of the revolutionary high throughput, high-speed automated cell counter – Cellaca™ MX.
Directly image and count calcein AM-labeled target cells in a 96-well plate using Celigo image cytometer. Concurrent imaging and analysis in 8 minutes.
By directly imaging and counting every cell in a well over a course of a drug treatment, the Celigo can perform the cytotoxicity assays in a label-free format.
